Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals: Growing Where It Matters
Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies, justifying a continued Buy rating. RIGL trades at a low P/E of ~7 despite robust 2025 revenue growth and positive cash flow, suggesting undervaluation relative to peers. Pipeline risk remains, as R289 for lower-risk MDS is still early-stage and highly speculative, with no imminent label expansions for existing drugs.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.8 per share a year ago.
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven primarily by the lead marketed drug Tavalisse.
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Rigel Pharmaceuticals climbs 59% in a year as Tavalisse anchors growth, oncology gains traction and 2026 guidance points to sustained momentum.
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026
Rigel Pharmaceuticals has benefitted from Tavalisse's sustained outperformance, driving increasing net income and attractive valuation metrics. Gavreto's recent flat performance is offset by RIGL's overall drug portfolio momentum and cash position improvement. R289 could have potential in lower-risk myelodysplastic syndromes, and additional clinical data provides a 2026 catalyst.
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rigel Pharma: Formulating A Game Plan For 2026
Rigel Pharmaceuticals delivered strong 2025 results, with Q3 revenue of $69.5M, net income of $27.9M, and cash of $137.1M. RIGL raised 2025 revenue guidance to $285M–$290M, projecting 55%–59% commercial growth, driven by TAVALISSE, REZLIDHIA, and GAVRETO. 2026 is expected to be a transition year, with flat revenue and declining EPS due to higher R&D spend, before a return to double-digit growth in 2027.
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
